Cholera vaccines
The methods and compositions of the present invention are directed to a vaccine against Vibrio cholerae comprised of V. cholerae outer membrane vesicles (OMVs). Such vaccines are relatively stable, facilitating distribution. Inventive methods generally include administration of a vaccine against Vibrio cholerae by intranasal, intraperitoneal, oral or intragastric routes. Such vaccines confer immunity to the individual, and when administered to pregnant subjects, can be conferred to the offspring of individuals.
1. A vaccine composition comprising isolated outer membrane vesicles obtained from Vibrio cholerae , which outer membrane vesicles comprise a lipid bilayer containing integral or surface associated outer membrane (OM) proteins, phospholipids and lipopolysaccharides of a Vibrio cholera strain that is either:
(a) the combination of O1 serogroup having the E1 Tor biotype and the Ogawa serotype; or
(b) the combination of O1 serogroup having the classical biotype and having the Ogawa serotype;
which strain carries a deletion of:
(c) one or more outer membrane proteins selected from the group consisting of ompU and ompT; or
(d) a toxR regulator of outer membrane proteins,
wherein the outer membrane vesicles have an altered protein content as compared with outer membrane vesicles shed from wild type Vibrio cholerae .
2. The vaccine composition of claim 1 , wherein the composition is suitable for intranasal administration.
3. The vaccine composition of claim 1 , further comprising one or more gene products not normally expressed in wild type strains of Vibrio cholerae.
4. The vaccine composition of claim 3 , wherein the one or more gene products include one or more gene products from at least one pathogen other than Vibrio cholerae .
5. The vaccine composition of claim 4 , wherein the at least one pathogen is selected from the group consisting of Shigellae, Salmonellae enterica, Campylobacter jejuni, Helicobacter pylori, E. coli , rotavirus, and combinations thereof.
6. The vaccine composition of claim 5 , wherein the at least one pathogen is or comprises E. coli selected from the group consisting of enterotoxigenic E. coli (ETEC), enteropathogenic E. coli (EPEC), enterohemorrhagic E. coli (EHEC), enteroinvasive E. coli (EIEC), enteroaggregative E. coli (EAggEc), and combinations thereof.
7. The vaccine composition of claim 5 , wherein the at least one pathogen is or comprises are Shigellae selected from the group consisting of Shigella dysenteriae, Shigella flexneri, Shigella boydii, Shigella sonnei , and combinations thereof.
8. A method comprising a step of administering to an individual an effective amount of a composition comprising outer membrane vesicles obtained from Vibrio cholera as recited in claim 1 .
9. The method of claim 8 , wherein immunity from cholera is conferred to the individual.
10. The method of claim 8 , wherein the composition further comprises one or more gene products not normally expressed in wild type strains of Vibrio cholerae .
11. The method of claim 8 , wherein immunity from cholera is conferred to one or more offspring of the individual.
12. The method of claim 11 , wherein the one or more gene products are gene products from pathogens other than Vibrio cholerae .
13. The method of claim 12 , wherein the gene product are gene products from pathogens selected from the group consisting of Shigellae, Salmonellae enterica, Campylobacter jejuni, Helicobacter pylori, E. coli , rotavirus, and combinations thereof.
14. The method of claim 13 , wherein the pathogens are E. coli selected from the group consisting of enterotoxigenic E. coli (ETEC), enteropathogenic E. coli (EPEC), enterohemorrhagic E. coli (EHEC), enteroinvasive E. coli (EIEC), enteroaggregative E. coli (EAggEC), and combinations thereof.
15. The method of claim 13 , wherein the pathogens are Shigellae selected from the group consisting of Shigella dysenteriae, Shigella flexneri, Shigella boydii, Shigella sonnei , and combinations thereof.
16. The method of claim 8 , wherein the route of administration is selected from the group consisting of intranasal, oral, subcutaneous, intradermal, intramuscular, intraperitoneal, and intragastric.
17. The method of claim 16 , wherein the route of administration is intranasal.
18. The method of claim 16 , wherein the route of administration is oral.
19. A method comprising steps of
(a) providing Vibrio cholerae cells grown in culture of a Vibrio cholera strain that is either:
(i) the combination of O1 serogroup having the E1 Tor biotype and the Ogawa serotype; or
(ii) the combination of O1 serogroup, having the classical biotype and having the Ogawa serotype, return which strain carries a deletion of:
(iii) one or more outer membrane proteins selected from the group consisting of ompU and ompT; or
(iv) of a toxR regulator of outer membrane proteins,
(b) preparing outer membrane vesicles from said Vibrio cholerae cells, which outer membrane vesicles have an altered protein content as compared with outer membrane vesicles shed from wild type Vibrio cholera ; and
(c) formulating a vaccine composition as recited in claim 1 , that comprises said outer membrane vesicles.
20. The method of claim 19 , wherein the Vibrio cholerae cells are of a strain selected from the group consisting of E7946 and O395.
21. The method of claim 19 , wherein the vaccine composition is suitable for intranasal administration.
22. The method of claim 19 , wherein the outer membrane vesicles contain one or more gene products not normally expressed in wild type strains of Vibrio cholerae .
23. The method of claim 19 , wherein the one or more gene products are gene products from pathogenic organisms other than Vibrio cholerae .
24. The method of claim 23 , wherein the one or more gene products are gene products from pathogenic organisms selected from the group consisting of Shigellae, Salmonellae enterica, Campylobacter jejuni, Helicobacter pylori, E. coli , rotavirus, and combinations thereof.
25. The method of claim 24 , wherein the pathogens are E. coli selected from the group consisting of enterotoxigenic E. coli (ETEC), enteropathogenic E. coli (EPEC), enterohemorrhagic E. coli (EHEC), enteroinvasive E. coli (EIEC), enteroaggregative E. coli (EAggEc), and combinations thereof.
26. The method of claim 24 , wherein the pathogens are Shigellae selected from the group consisting of Shigella dysenteriae, Shigella flexneri, Shigella boydii, Shigella sonnei , and combinations thereof.